In this presentation, we unveil the outcomes of an internal initiative centered on the non-proprietary ADC Trastuzumab-MC-Val-Cit-PAB-MMAE. Our focus will encompass the entire ADC synthesis process, delving into the structural intricacies through subunit analysis and peptide mapping. Additionally, we will shed light on the aggregation analysis, providing insights into the stability and quality of the ADC. Through rigorous examination and meticulous characterization, our investigation offers a comprehensive understanding of Trastuzumab-MC-Val-Cit-PAB-MMAE, contributing valuable insights to the field of ADC development.